Nursing Clinical Insights Into the Benefits and Challenges of EGFR TKIs in the Treatment of NSCLC

Lung cancer is the leading cause of cancer death. Approximately 85% of lung cancer cases are non–small cell lung cancer (NSCLC), 10% to 15% of which are epidermal growth factor receptor (EGFR) mutation positive. The development of EGFR inhibitors (eg, tyrosine kinase inhibitors [TKIs]) has led to targeted therapy, advancing the management of NSCLC. Unfortunately, the disease often develops resistance to some of these therapies; however, significant progress has been made in the treatment of NSCLC.

Recent advances in next-generation EGFR TKIs have shown promising results in patients with EGFR mutation–positive refractory NSCLC.

ENROLL IN THIS ACTIVITY

 

Understanding Treatment Strategies for Squamous Cell Carcinoma of the Head and Neck

The complexity of managing squamous cell carcinoma of the head and neck (SCCHN) requires a multidisciplinary team. Support and services for the treatment of patients with SCCHN may include nutritional support, speech and swallowing therapy, and dental care, among others.  Additionally, the American Cancer Society published new guidelines for head and neck cancer survivorship care in March 2016.

The goal of this activity is to close educational gaps by providing clinicians with the latest evidence-based data about current and emerging agents and multidisciplinary approaches for the treatment of squamous cell carcinoma of the head and neck.  ENROLL IN THIS ACIVITY

 

Managing Unresectable Hepatocellular Carcinoma: Focus on Systemic Therapies

Advances in the understanding of the molecular pathogenesis of hepatocellular carcinoma (HCC) have broadened the potential for effective molecular targeted therapies. However, the management of unresectable HCC continues to be challenging. It is important that healthcare providers involved in the management of HCC have a good understanding of the current therapeutic options and that they stay up-to-date regarding the emerging therapies for unresectable disease.  However, in light of the complexity of treatment and the rapid pace of treatment-related developments, this can be a difficult goal to achieve and maintain. 

This activity will provide updates on approved and investigational therapies for unresectable HCC, discuss the importance of multidisciplinary and interprofessional collaboration, and present useful tips on using a shared decision-making approach in the management of HCC. 
VIEW THIS ACTIVITY
 

Paving the Way to Better Choices for Veterans With Lung Cancer: A Shared Decision-Making Approach to Treatment

Approximately 35,000 new cases of cancer occur in military veterans each year; cancer is the second leading cause of death among military veterans. According to the late Rear Admiral Philip J. Coady, USN, former Chairman of the Board of Directors of the Lung Cancer Alliance, “lung cancer is an urgent priority among veterans. 

Because clinicians who work in VA facilities may not realize the importance of patient engagement and SDM with veterans and their caregivers, education will also be provided to assist clinicians in engaging military veterans in treatment decisions using SDM approaches and prioritizing the timeliness of care, coordination of care, screening, and access to palliative care for military veterans.  VIEW THIS ACTIVITY

 

Making Progress for Improving Patient Lives: Clinical Advances in the First-Line Treatment of Advanced Squamous Non—Small Cell Lung Cancer

The goal of this activity is to close educational gaps by providing clinicians with the latest evidence-based data about current and emerging agents for the first-line treatment of advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Clinicians need to remain apprised of emerging data offering additional treatment options for NSCLC, specifically for the first-line treatment of advanced or metastatic squamous NSCLC where few advances have been made over the past two decades and few options exist.   VIEW THIS ACTIVITY

 

Failure Is Not an Option: Selecting Optimal Stem Cell Mobilization Strategies for Multiple Myeloma and Non-Hodgkin Lymphoma

There are many opportunities for healthcare professionals to improve the probability of successful mobilization in their patients with MM or NHL who are eligible for aHSCT. This activity will address available mobilization regimens for stem cell collection, identifying patients at risk for poor mobilization, and guidance for optimal regimen selection for each of their patients based on patient characteristics and cost of treatment. 

This activity is intended for medical oncologists, oncology nurses, transplant specialists, and other healthcare providers who treat or manage patients under consideration for stem cell mobilization and transplantation.  ENROLL IN THIS ACIVITY

 

Conquering Therapeutic Challenges in Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex: The Power of mTOR Inhibition

The goal of this activity is to close knowledge gaps on how to effectively treat and manage subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) and to provide clinicians with the necessary information to confidently use current and emerging agents to reduce symptoms while minimizing adverse effects. 

TSC is an autosomal dominant genetic disorder characterized by the systemic growth of benign, noninvasive legions, or hamartomas. Common sites of lesion growth include the brain, skin, kidney, heart, lung, and liver. TSC is frequently diagnosed before patients are 15 months old. The central nervous system is the most commonly affected system, affecting 85% to 90% of children and adolescents.  ENROLL IN THIS ACTIVITY

 

Transforming the Quality of Care for Patients With Immune Thrombocytopenia: Therapeutic and Management Approaches Making a Difference

Immune thrombocytopenia (ITP), once known as idiopathic thrombocytopenic purpura, is an autoimmune disorder that can occur acutely or chronically, and ranges in severity from mild to life-threatening. 

New treatments for both adults and children with ITP are continuously becoming available, challenging clinicians to optimally balance efficacy and safety when developing individualized treatment plans. This Virtual Grand Rounds initiative aims to close educational gaps and provide clinicians with up-to-date knowledge on current and emerging treatment strategies to make informed clinical choices to confidently treat and manage ITP.  ENROLL IN THIS ACTIVITY

 

Integrating the Latest Advances Into Clinical Practice: Data and Expert Insights From the 2016 Meeting on Genitourinary Cancers in San Francisco - Bladder Cancer

The goal of this activity is to provide clinicians with the latest clinical advances and emerging research in bladder cancer, as well as strategies to optimally integrate evolving evidence into clinical practice to improve the quality of care delivery.

In 2015, there were an estimated 138,710 new cases of urinary system cancers in the United States, with an estimated 30,970 deaths. Having access to the most recent clinical advances in GU malignancies is crucial to making informed and timely treatment decisions. This activity will highlight the most exciting and compelling data in bladder cancer, and provide insights on how these clinical advances may be practice changing.  ENROLL IN THIS ACTIVITY

 

Clinical Debates and Consensus Recommendations on the Use of Antiangiogenic Agents in Lung Cancer: A Focus on the Elderly Patient

This interactive lecture activity is designed to afford medical oncologists, thoracic oncologists, surgical oncologists, radiation oncologists, and other healthcare providers who treat or manage non–small cell lung cancer (NSCLC) the opportunity to engage in interdisciplinary dialogue with their peers and interact with experts from outside their institutions.

Discussions will focus on the angiogenesis pathway in NSCLC, the implementation of vascular endothelial growth factor (VEGF) inhibitors in older patients with NSCLC and its controversies, clinical results with use of VEGF inhibitors in older patients, and factors causing unintended treatment bias.  VIEW THIS ACTIVITY

 

Recent Courses

Title Credit Type Release and expiration date
Current and Future Directions in the Treatment of Colorectal Cancer
  • 1.00 ACPE credit
  • 1.00 ANCC credit
  • 1.00 Attendance credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 02/21/2017 to 07/19/2018
Incorporating CDK 4/6 Inhibitors in the Treatment of Estrogen Receptor–Positive Breast Cancer: Considerations for Nurses, Patients, and Families
  • 1.00 ANCC credit
  • 1.00 Attendance credit
Enduring 02/07/2017 to 07/09/2018
Current and Future Directions in the Treatment of Pulmonary Neuroendocrine Tumors
  • 1.00 ANCC credit
  • 1.00 Attendance credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 01/18/2017 to 02/08/2018
Nursing Clinical Insights Into the Benefits and Challenges of EGFR TKIs in the Treatment of NSCLC
  • 0.50 ANCC credits
  • 0.50 Attendance credits
Enduring 01/17/2017 to 01/16/2018
The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
  • 1.00 ANCC credit
  • 1.00 Attendance credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 01/06/2017 to 09/29/2017
Expanded Treatment Options for Metastatic Pancreatic Cancer: Evidence-Based Updates
  • 1.00 ACPE credit
  • 1.00 ANCC credit
  • 1.00 Attendance credit
  • 1.00 AMA PRA Category 1 Credit™ credit
Enduring 12/21/2016 to 04/12/2018

Pages

Subscribe and receive timely updates

Returning AXIS Users

If you are an active AXISMedEd.com member, this site has been updated with enhanced functionality and security. You will need to create a new user profile and password. We apologize for any inconvenience this may cause. We truly appreciate you using AXISMedEd.com to meet your educational needs.

View the Courses You Have Completed

    Please login or create an account to view your activities.